Loading...
•
Dec 31, 2021
Voyager Therapeutics Q4 2021 Earnings Report
Voyager Therapeutics reported Q4 2021 financial results and provided business updates.
Key Takeaways
Voyager Therapeutics reported collaboration revenue of $28.1 million for the fourth quarter of 2021, compared to $6.5 million for the same period in 2020, with a net income of $5.7 million for the fourth quarter of 2021, compared to a net loss of $15.9 million for the same period of 2020.
License option agreement with Novartis for target-specific access to TRACERTM next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets
Novartis agreement marks second recent major transaction to leverage Voyager’s TRACER technology following October 2021 Pfizer agreement
Strengthened leadership with appointment of Al Sandrock, Jr., M.D., Ph.D. to Board of Directors and Board Executive Committee, promotion of Robin Swartz to chief operating officer
Cash runway extended into 2024 with $84 million aggregate upfront payments from Novartis and Pfizer transactions
Revenue by Segment
Forward Guidance
Voyager expects that its cash, cash equivalents, and marketable securities inclusive of upfront payments anticipated to be received under the Novartis license option agreement will be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...